clinical trial · NCT07438496
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Janssen Research & Development, LLC·phase3·recruiting·n = 600
Lupus Erythematosus, SystemicNipocalimabPlaceboStandard of care treatment
brief summary
The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).
started
Mar 5, 2026
primary completion
Dec 6, 2028
completion
Nov 7, 2031
last updated
Apr 13, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol